GoodRx Appoints Healthcare Industry Veteran, Wendy Barnes, as New Chief Executive Officer
16 Dezembro 2024 - 6:05PM
Business Wire
Wendy Barnes, Current CEO of RxBenefits, Brings
Extensive Healthcare Management Experience to the Company
GoodRx Holdings, Inc. (NASDAQ: GDRX), the leading prescription
savings platform in the U.S., today announced that Wendy Barnes has
been appointed as President and Chief Executive Officer, effective
January 1, 2025. Wendy brings more than 30 years of leadership
experience across the pharmacy and medical benefit industry to her
new role.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20241216730604/en/
Wendy Barnes (Photo: Business Wire)
Wendy will join GoodRx following her role as CEO of RxBenefits,
where she led the company in providing pharmacy benefit support to
more than 2,000 self-insured clients comprised of more than three
million lives. Under her guidance, RxBenefits became a leading
entity providing tailored pharmacy benefit solutions that promote
affordability and transparency. Before that, as President of
Express Scripts Pharmacy, Wendy oversaw the service, operation, and
financial success of the organization’s multiple pharmacies on
behalf of 100 million members. Wendy also served as Group Vice
President at Rite Aid, where she was responsible for all aspects of
managed care, including contracting, enhancing relationships with
managed care organizations, overseeing pharmacy benefit managers
and third-party payers, and developing strategic partnerships.
“Wendy is joining GoodRx at a pivotal moment – both for the
healthcare industry and for GoodRx. In a world where conventional
insurance coverage is increasingly restrictive, and patients and
healthcare professionals are bearing increasing costs and time
burdens, GoodRx offers a complement to insurance that fills the
gaps that existing systems don’t cover and helps Americans save
both time and money,” said Scott Wagner, Interim CEO at GoodRx.
“Wendy has the expertise, vision, and leadership to help GoodRx
grow in unique and valuable ways, both for our customers and as a
business. I’m excited for Wendy and I’m particularly excited for
GoodRx.”
Wendy's career highlights include her effective leadership roles
at RxBenefits, Express Scripts, Rite Aid and Pfizer, leading
extensive pharmacy operations and simplifying and improving patient
healthcare experiences. Wendy also served for 10 years as a Medical
Service Corps Officer in the United States Air Force.
"I am thrilled to join GoodRx and contribute to its mission of
making healthcare more affordable for millions of Americans," said
Wendy Barnes, the newly appointed President and CEO of GoodRx.
"With the evolving challenges in healthcare delivery and
management, I look forward to working with our talented executive
leadership team to foster growth and innovation at GoodRx and
within the industry. We have a tremendous opportunity to free
Americans from friction in getting medication.”
In her role as CEO, Wendy will focus on advancing GoodRx’s
strategic initiatives, with particular attention on bringing all
brand affordability programs onto the GoodRx platform, expanding
GoodRx’s product experience with healthcare professionals, and
enriching partnerships with retail pharmacies, insurers, and
pharmaceutical manufacturers to help save Americans time and money.
Driven by a steadfast commitment to making healthcare more
accessible and affordable, Wendy aims to build a better patient
experience and help fill gaps within the existing system.
“As we embark on this transition, I want to thank Scott for his
hard work and huge impact over the last year and a half as our
Interim CEO. His leadership and deep business expertise has been
felt both inside and outside the walls of GoodRx,” said Trevor
Bezdek, Co-founder and Chairman of GoodRx. “As we look ahead to the
next phase of growth, I’m confident and enthusiastic that Wendy’s
experience and dedication to improving patient lives will drive
GoodRx’s mission forward.”
About GoodRx
GoodRx is the leading prescription savings platform in the U.S.
Trusted by more than 25 million consumers and 750,000 healthcare
professionals annually, GoodRx provides access to savings and
affordability options for generic and brand-name medications at
more than 70,000 pharmacies nationwide, as well as comprehensive
healthcare research and information. Since 2011, GoodRx has helped
consumers save over $75 billion on the cost of their
prescriptions.
GoodRx periodically posts information that may be important to
investors on its investor relations website at
https://investors.goodrx.com. We intend to use our website as a
means of disclosing material nonpublic information and for
complying with our disclosure obligations under Regulation FD.
Accordingly, investors and potential investors are encouraged to
consult GoodRx’s website regularly for important information, in
addition to following GoodRx’s press releases, filings with the
Securities and Exchange Commission (the “SEC”) and public
conference calls and webcasts. The information contained on, or
that may be accessed through, GoodRx’s website is not incorporated
by reference into, and is not a part of, this press release.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including, without limitation,
statements regarding anticipated consumer savings, convenience and
accessibility; the new CEO appointment and related benefits and
values; and our plans, expectations and objectives. These
statements are neither promises nor guarantees, but involve known
and unknown risks, uncertainties and other important factors that
may cause our actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements, including, but not limited to, risks relating to our
ability to achieve broad market education and change consumer
purchasing habits; changes in medication pricing and pricing
structures; our reliance on a limited number of industry
participants; and the important factors discussed under the caption
“Risk Factors” in our Annual Report on Form 10-K for the year ended
December 31, 2023, and our other filings with the SEC. Any such
forward-looking statements are based on current expectations,
projections and estimates as of the date of this press release.
While we may elect to update such forward-looking statements at
some point in the future, we disclaim any obligation to do so, even
if subsequent events cause our views to change.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241216730604/en/
press@goodrx.com
GoodRx (NASDAQ:GDRX)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
GoodRx (NASDAQ:GDRX)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024